- In a paper published online today in PNAS, scientists from the European Molecular Biology Laboratory (EMBL) in Hamburg, Germany, reveal new insights into the workings of enzymes from a group of bacteria including Mycobacterium tuberculosis, the bacterium that causes tuberculosis.
- Standardized screening rule for TB in people living with HIV in low income settings
- A new study found that there is a serious increased risk of side effects requiring hospitalization in people over the age of 65 who are going through latent tuberculosis infection therapy, according to a study published in CMAJ.
- New research findings which show that vitamin D can speed up antibiotic treatment of tuberculosis (TB) have been revealed by scientists at Barts and The London School of Medicine and Dentistry.
- Although a clear association of tuberculosis with lung cancer remains to be established, a new study published in the January issue of the Journal of Thoracic Oncology provides compelling evidence of increased lung cancer risk among people with tuberculosis.
- The risk of tuberculosis (TB) and latent TB (in which the bacteria that cause TB lie dormant but can reactivate later to cause active TB disease) is higher in the prison population than in the general population.
- A team of researchers from Spain and Latin America have synthesized two iron compounds that inhibit the in vitro growth of Mycobacterium tuberculosis, the bacteria that causes tuberculosis. Due their low level of toxicity in mammel cells, the compounds could be used in the future as therapeutic agents and hospital disinfectants.
- China had an estimated 1.3 million new cases of tuberculosis (TB) in 2008, of which 112,000 were multi-drug resistant (MDR-TB). Over the period 2001, TB was the second largest cause of death among China's 39 notifiable communicable diseases.
- A key enzyme in Mycobacterium tuberculosis that enables the microbe to reproduce rapidly could be a golden target for new drugs against tuberculosis (TB), according to a study published inMicrobiology on 17 November.
- New research being presented at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will feature an inhalable dry powder antibiotic that when used alone or with current treatments may significantly reduce treatment for tuberculosis (TB) and multi-drug resistant TB.
- Tuberculosis, which killed an estimated 1.7 million people last year, can be cured in six months if detected and treated early, says the World Health Organisation.
- Researchers at the University of California, San Diego School of Medicine and the University of Leeds have linked hundreds of federally approved drugs to more than 1,000 proteins in Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), opening new avenues to repurpose these drugs to treat TB.
Tuberculosis, MTB, or TB (short for tubercle bacillus) is a common, and in many cases lethal, infectious disease caused by various strains of mycobacteria, usually Mycobacterium tuberculosis. Tuberculosis usually attacks the lungs but can also affect other parts of the body. It is spread through the air when people who have an active MTB infection cough, sneeze, or otherwise transmit their saliva through the air.